Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae.

Hübner MP, Koschel M, Struever D, Nikolov V, Frohberger SJ, Ehrens A, Fendler M, Johannes I, von Geldern TW, Marsh K, Turner JD, Taylor MJ, Ward SA, Pfarr K, Kempf DJ, Hoerauf A.

PLoS Negl Trop Dis. 2019 Aug 5;13(8):e0007636. doi: 10.1371/journal.pntd.0007636. eCollection 2019 Aug.

2.

Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis.

Taylor MJ, von Geldern TW, Ford L, Hübner MP, Marsh K, Johnston KL, Sjoberg HT, Specht S, Pionnier N, Tyrer HE, Clare RH, Cook DAN, Murphy E, Steven A, Archer J, Bloemker D, Lenz F, Koschel M, Ehrens A, Metuge HM, Chunda VC, Ndongmo Chounna PW, Njouendou AJ, Fombad FF, Carr R, Morton HE, Aljayyoussi G, Hoerauf A, Wanji S, Kempf DJ, Turner JD, Ward SA.

Sci Transl Med. 2019 Mar 13;11(483). pii: eaau2086. doi: 10.1126/scitranslmed.aau2086.

PMID:
30867321
3.

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity.

von Geldern TW, Morton HE, Clark RF, Brown BS, Johnston KL, Ford L, Specht S, Carr RA, Stolarik DF, Ma J, Rieser MJ, Struever D, Frohberger SJ, Koschel M, Ehrens A, Turner JD, Hübner MP, Hoerauf A, Taylor MJ, Ward SA, Marsh K, Kempf DJ.

PLoS Negl Trop Dis. 2019 Feb 28;13(2):e0007159. doi: 10.1371/journal.pntd.0007159. eCollection 2019 Feb.

4.

Longitudinal MRI Evaluation of Ischemic Stroke in the Basal Ganglia of a Rhesus Macaque (Macaca mulatta) with Seizures.

Li CX, Kempf DJ, Tong FC, Yan Y, Xu Z, Connor-Stroud FR, Ford BD, Howell LL, Zhang X.

Comp Med. 2018 Dec 1;68(6):496-502. doi: 10.30802/AALAS-CM-18-000004. Epub 2018 Nov 28.

5.

Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.

Hidaka K, Kimura T, Sankaranarayanan R, Wang J, McDaniel KF, Kempf DJ, Kameoka M, Adachi M, Kuroki R, Nguyen JT, Hayashi Y, Kiso Y.

J Med Chem. 2018 Jun 28;61(12):5138-5153. doi: 10.1021/acs.jmedchem.7b01709. Epub 2018 Jun 11.

PMID:
29852069
6.

Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.

Hulverson MA, Choi R, Arnold SLM, Schaefer DA, Hemphill A, McCloskey MC, Betzer DP, Müller J, Vidadala RSR, Whitman GR, Rivas KL, Barrett LK, Hackman RC, Love MS, McNamara CW, Shaughnessy TK, Kondratiuk A, Kurnick M, Banfor PN, Lynch JJ, Freiberg GM, Kempf DJ, Maly DJ, Riggs MW, Ojo KK, Van Voorhis WC.

Int J Parasitol. 2017 Oct;47(12):753-763. doi: 10.1016/j.ijpara.2017.08.006. Epub 2017 Sep 9.

7.

Crystal structure of full-length Zika virus NS5 protein reveals a conformation similar to Japanese encephalitis virus NS5.

Upadhyay AK, Cyr M, Longenecker K, Tripathi R, Sun C, Kempf DJ.

Acta Crystallogr F Struct Biol Commun. 2017 Mar 1;73(Pt 3):116-122. doi: 10.1107/S2053230X17001601. Epub 2017 Feb 21.

8.

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Park Y, Pacitto A, Bayliss T, Cleghorn LA, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M, Donini S, Blundell TL, Ascher DB, Rhee K, Breda A, Zhou N, Dartois V, Jonnala SR, Via LE, Mizrahi V, Epemolu O, Stojanovski L, Simeons F, Osuna-Cabello M, Ellis L, MacKenzie CJ, Smith AR, Davis SH, Murugesan D, Buchanan KI, Turner PA, Huggett M, Zuccotto F, Rebollo-Lopez MJ, Lafuente-Monasterio MJ, Sanz O, Diaz GS, Lelièvre J, Ballell L, Selenski C, Axtman M, Ghidelli-Disse S, Pflaumer H, Bösche M, Drewes G, Freiberg GM, Kurnick MD, Srikumaran M, Kempf DJ, Green SR, Ray PC, Read K, Wyatt P, Barry CE 3rd, Boshoff HI.

ACS Infect Dis. 2017 Jan 13;3(1):18-33. doi: 10.1021/acsinfecdis.6b00103. Epub 2016 Oct 17.

9.

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.

Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, Schultz TL, Huang W, Zhang Z, Scheele S, DeRocher AE, Choi R, Barrett LK, Siddaramaiah LK, Hol WG, Fan E, Merritt EA, Parsons M, Freiberg G, Marsh K, Kempf DJ, Carruthers VB, Isoherranen N, Doggett JS, Van Voorhis WC, Maly DJ.

J Med Chem. 2016 Jul 14;59(13):6531-46. doi: 10.1021/acs.jmedchem.6b00760. Epub 2016 Jul 1.

10.

Accuracy of Human and Veterinary Point-of-Care Glucometers for Use in Rhesus Macaques (Macaca mulatta), Sooty Mangabeys (Cercocebus atys), and Chimpanzees (Pan troglodytes).

Clemmons EA, Stovall MI, Owens DC, Scott JA, Jones-Wilkes AC, Kempf DJ, Ethun KF.

J Am Assoc Lab Anim Sci. 2016;55(3):346-53.

11.

An Enhanced Model of Middle Cerebral Artery Occlusion in Nonhuman Primates Using an Endovascular Trapping Technique.

Tong FC, Zhang X, Kempf DJ, Yepes MS, Connor-Stroud FR, Zola S, Howell L.

AJNR Am J Neuroradiol. 2015 Dec;36(12):2354-9. doi: 10.3174/ajnr.A4448. Epub 2015 Sep 17.

12.

A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.

Ojo KK, Eastman RT, Vidadala R, Zhang Z, Rivas KL, Choi R, Lutz JD, Reid MC, Fox AM, Hulverson MA, Kennedy M, Isoherranen N, Kim LM, Comess KM, Kempf DJ, Verlinde CL, Su XZ, Kappe SH, Maly DJ, Fan E, Van Voorhis WC.

J Infect Dis. 2014 Jan 15;209(2):275-84. doi: 10.1093/infdis/jit522. Epub 2013 Oct 10.

13.

Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A.

DeGoey DA, Betebenner DA, Grampovnik DJ, Liu D, Pratt JK, Tufano MD, He W, Krishnan P, Pilot-Matias TJ, Marsh KC, Molla A, Kempf DJ, Maring CJ.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3627-30. doi: 10.1016/j.bmcl.2013.04.009. Epub 2013 Apr 10.

PMID:
23642966
14.

Effects of extended-release injectable naltrexone on self-injurious behavior in rhesus macaques (Macaca mulatta).

Kempf DJ, Baker KC, Gilbert MH, Blanchard JL, Dean RL, Deaver DR, Bohm RP Jr.

Comp Med. 2012 Jun;62(3):209-17.

15.

Double-outlet right ventricle and double septal defects in a Rhesus macaque (Macaca mulatta).

Liu DX, Gilbert MH, Kempf DJ, Didier PJ.

J Vet Diagn Invest. 2012 Jan;24(1):188-91. doi: 10.1177/1040638711425951. Epub 2011 Dec 6.

16.

Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.

Krueger AC, Madigan DL, Beno DW, Betebenner DA, Carrick R, Green BE, He W, Liu D, Maring CJ, McDaniel KF, Mo H, Molla A, Motter CE, Pilot-Matias TJ, Tufano MD, Kempf DJ.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2212-5. doi: 10.1016/j.bmcl.2012.01.096. Epub 2012 Feb 2.

PMID:
22342631
17.

P1-substituted symmetry-based human immunodeficiency virus protease inhibitors with potent antiviral activity against drug-resistant viruses.

Degoey DA, Grampovnik DJ, Chen HJ, Flosi WJ, Klein LL, Dekhtyar T, Stoll V, Mamo M, Molla A, Kempf DJ.

J Med Chem. 2011 Oct 27;54(20):7094-104. doi: 10.1021/jm201109t. Epub 2011 Sep 21.

PMID:
21899332
18.

Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.

Hutchinson DK, Flentge CA, Donner PL, Wagner R, Maring CJ, Kati WM, Liu Y, Masse SV, Middleton T, Mo H, Montgomery D, Jiang WW, Koev G, Beno DW, Stewart KD, Stoll VS, Molla A, Kempf DJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1876-9. doi: 10.1016/j.bmcl.2010.12.067. Epub 2011 Jan 13.

PMID:
21316235
19.

Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.

Young TP, Parkin NT, Stawiski E, Pilot-Matias T, Trinh R, Kempf DJ, Norton M.

Antimicrob Agents Chemother. 2010 Nov;54(11):4903-6. doi: 10.1128/AAC.00906-10. Epub 2010 Aug 30.

20.

Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats.

Yang Y, Dahly-Vernon AJ, Blomme EA, Lai-Zhang J, Kempf DJ, Marsh KC, Harrington YA, Nye SH, Evans DL, Roman RJ, Jacob HJ, Waring JF.

Vet J. 2010 Jul;185(1):75-82. doi: 10.1016/j.tvjl.2010.04.017. Epub 2010 May 23.

PMID:
20547082
21.

Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.

Waring JF, Ciurlionis R, Marsh K, Klein LL, Degoey DA, Randolph JT, Spear B, Kempf DJ.

Arch Toxicol. 2010 Apr;84(4):263-70. doi: 10.1007/s00204-010-0527-7. Epub 2010 Mar 6.

PMID:
20213465
22.

Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.

Stewart KD, Huth JR, Ng TI, McDaniel K, Hutchinson RN, Stoll VS, Mendoza RR, Matayoshi ED, Carrick R, Mo H, Severin J, Walter K, Richardson PL, Barrett LW, Meadows R, Anderson S, Kohlbrenner W, Maring C, Kempf DJ, Molla A, Olejniczak ET.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):612-7. doi: 10.1016/j.bmcl.2009.11.076. Epub 2009 Nov 20.

PMID:
20004576
23.

Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.

Hidaka K, Kimura T, Abdel-Rahman HM, Nguyen JT, McDaniel KF, Kohlbrenner WE, Molla A, Adachi M, Tamada T, Kuroki R, Katsuki N, Tanaka Y, Matsumoto H, Wang J, Hayashi Y, Kempf DJ, Kiso Y.

J Med Chem. 2009 Dec 10;52(23):7604-17. doi: 10.1021/jm9005115.

PMID:
19954246
24.

Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.

Flentge CA, Randolph JT, Huang PP, Klein LL, Marsh KC, Harlan JE, Kempf DJ.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5444-8. doi: 10.1016/j.bmcl.2009.07.118. Epub 2009 Jul 30.

PMID:
19679477
25.

Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.

Randolph JT, Flentge CA, Huang PP, Hutchinson DK, Klein LL, Lim HB, Mondal R, Reisch T, Montgomery DA, Jiang WW, Masse SV, Hernandez LE, Henry RF, Liu Y, Koev G, Kati WM, Stewart KD, Beno DW, Molla A, Kempf DJ.

J Med Chem. 2009 May 28;52(10):3174-83. doi: 10.1021/jm801485z.

PMID:
19402666
26.

Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

DeGoey DA, Grampovnik DJ, Flosi WJ, Marsh KC, Wang XC, Klein LL, McDaniel KF, Liu Y, Long MA, Kati WM, Molla A, Kempf DJ.

J Med Chem. 2009 May 14;52(9):2964-70. doi: 10.1021/jm900080g.

PMID:
19348416
27.

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

Degoey DA, Grampovnik DJ, Flentge CA, Flosi WJ, Chen HJ, Yeung CM, Randolph JT, Klein LL, Dekhtyar T, Colletti L, Marsh KC, Stoll V, Mamo M, Morfitt DC, Nguyen B, Schmidt JM, Swanson SJ, Mo H, Kati WM, Molla A, Kempf DJ.

J Med Chem. 2009 Apr 23;52(8):2571-86. doi: 10.1021/jm900044w.

PMID:
19323562
28.

Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.

Wagner R, Larson DP, Beno DW, Bosse TD, Darbyshire JF, Gao Y, Gates BD, He W, Henry RF, Hernandez LE, Hutchinson DK, Jiang WW, Kati WM, Klein LL, Koev G, Kohlbrenner W, Krueger AC, Liu J, Liu Y, Long MA, Maring CJ, Masse SV, Middleton T, Montgomery DA, Pratt JK, Stuart P, Molla A, Kempf DJ.

J Med Chem. 2009 Mar 26;52(6):1659-69. doi: 10.1021/jm8010965.

PMID:
19226162
29.

Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives.

Hutchinson DK, Rosenberg T, Klein LL, Bosse TD, Larson DP, He W, Jiang WW, Kati WM, Kohlbrenner WE, Liu Y, Masse SV, Middleton T, Molla A, Montgomery DA, Beno DW, Stewart KD, Stoll VS, Kempf DJ.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3887-90. doi: 10.1016/j.bmcl.2008.06.043. Epub 2008 Jun 18.

PMID:
18599294
30.

Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.

Randolph JT, Zhang X, Huang PP, Klein LL, Kurtz KA, Konstantinidis AK, He W, Kati WM, Kempf DJ.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2745-50. doi: 10.1016/j.bmcl.2008.02.053. Epub 2008 Feb 26.

PMID:
18375121
31.

Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase.

Donner PL, Xie Q, Pratt JK, Maring CJ, Kati W, Jiang W, Liu Y, Koev G, Masse S, Montgomery D, Molla A, Kempf DJ.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2735-8. doi: 10.1016/j.bmcl.2008.02.064. Epub 2008 Mar 4.

PMID:
18362072
32.

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3879-84. doi: 10.1073/pnas.0800050105. Epub 2008 Mar 10.

33.

Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.

Krueger AC, Xu Y, Kati WM, Kempf DJ, Maring CJ, McDaniel KF, Molla A, Montgomery D, Kohlbrenner WE.

Bioorg Med Chem Lett. 2008 Mar 1;18(5):1692-5. doi: 10.1016/j.bmcl.2008.01.048. Epub 2008 Jan 18.

PMID:
18242993
34.

Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.

Dekhtyar T, Ng TI, Lu L, Masse S, DeGoey DA, Flosi WJ, Grampovnik DJ, Klein LL, Kempf DJ, Molla A.

Antimicrob Agents Chemother. 2008 Apr;52(4):1337-44. doi: 10.1128/AAC.01132-07. Epub 2008 Jan 22.

35.

A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor.

Healan-Greenberg C, Waring JF, Kempf DJ, Blomme EA, Tirona RG, Kim RB.

Drug Metab Dispos. 2008 Mar;36(3):500-7. Epub 2007 Dec 20.

PMID:
18096673
36.

Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.

He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A.

Antimicrob Agents Chemother. 2008 Mar;52(3):1101-10. Epub 2007 Dec 17.

37.

Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors.

Bosse TD, Larson DP, Wagner R, Hutchinson DK, Rockway TW, Kati WM, Liu Y, Masse S, Middleton T, Mo H, Montgomery D, Jiang W, Koev G, Kempf DJ, Molla A.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):568-70. Epub 2007 Nov 28.

PMID:
18068361
38.

Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.

Chen CM, He Y, Lu L, Lim HB, Tripathi RL, Middleton T, Hernandez LE, Beno DW, Long MA, Kati WM, Bosse TD, Larson DP, Wagner R, Lanford RE, Kohlbrenner WE, Kempf DJ, Pilot-Matias TJ, Molla A.

Antimicrob Agents Chemother. 2007 Dec;51(12):4290-6. Epub 2007 Oct 1.

39.

Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.

Kempf DJ, Klein C, Chen HJ, Klein LL, Yeung C, Randolph JT, Lau YY, Chovan LE, Guan Z, Hernandez L, Turner TM, Dandliker PJ, Marsh KC.

Antivir Chem Chemother. 2007;18(3):163-7.

PMID:
17626600
40.

Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.

King MS, Rode R, Cohen-Codar I, Calvez V, Marcelin AG, Hanna GJ, Kempf DJ.

Antimicrob Agents Chemother. 2007 Sep;51(9):3067-74. Epub 2007 Jun 18. Erratum in: Antimicrob Agents Chemother. 2008 Feb;52(2):811.

41.

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW.

PLoS Pathog. 2007 Apr;3(4):e46.

42.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives.

Krueger AC, Madigan DL, Green BE, Hutchinson DK, Jiang WW, Kati WM, Liu Y, Maring CJ, Masse SV, McDaniel KF, Middleton TR, Mo H, Molla A, Montgomery DA, Ng TI, Kempf DJ.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2289-92. Epub 2007 Jan 27.

PMID:
17300933
43.

Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery.

Stewart KD, Steffy K, Harris K, Harlan JE, Stoll VS, Huth JR, Walter KA, Gramling-Evans E, Mendoza RR, Severin JM, Richardson PL, Barrett LW, Matayoshi ED, Swift KM, Betz SF, Muchmore SW, Kempf DJ, Molla A.

J Comput Aided Mol Des. 2007 Jan-Mar;21(1-3):121-30. Epub 2007 Feb 9.

PMID:
17294246
44.
45.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring.

Rockway TW, Zhang R, Liu D, Betebenner DA, McDaniel KF, Pratt JK, Beno D, Montgomery D, Jiang WW, Masse S, Kati WM, Middleton T, Molla A, Maring CJ, Kempf DJ.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3833-8. Epub 2006 May 2.

PMID:
16650984
46.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides.

Krueger AC, Madigan DL, Jiang WW, Kati WM, Liu D, Liu Y, Maring CJ, Masse S, McDaniel KF, Middleton T, Mo H, Molla A, Montgomery D, Pratt JK, Rockway TW, Zhang R, Kempf DJ.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3367-70. Epub 2006 May 2.

PMID:
16650764
47.

Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.

Randolph JT, Huang PP, Flosi WJ, DeGoey D, Klein LL, Yeung CM, Flentge C, Sun M, Zhao C, Dekhtyar T, Mo H, Colletti L, Kati W, Marsh KC, Molla A, Kempf DJ.

Bioorg Med Chem. 2006 Jun 15;14(12):4035-46. Epub 2006 Feb 28.

PMID:
16504523
48.

Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors.

Kempf DJ, Waring JF, Morfitt DC, Werner P, Ebert B, Mitten M, Nguyen B, Randolph JT, DeGoey DA, Klein LL, Marsh K.

Antimicrob Agents Chemother. 2006 Feb;50(2):762-4.

49.

Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.

Zhao C, Sham HL, Sun M, Stoll VS, Stewart KD, Lin S, Mo H, Vasavanonda S, Saldivar A, Park C, McDonald EJ, Marsh KC, Klein LL, Kempf DJ, Norbeck DW.

Bioorg Med Chem Lett. 2005 Dec 15;15(24):5499-503. Epub 2005 Oct 3.

PMID:
16203141
50.

Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.

Maring CJ, Stoll VS, Zhao C, Sun M, Krueger AC, Stewart KD, Madigan DL, Kati WM, Xu Y, Carrick RJ, Montgomery DA, Kempf-Grote A, Marsh KC, Molla A, Steffy KR, Sham HL, Laver WG, Gu YG, Kempf DJ, Kohlbrenner WE.

J Med Chem. 2005 Jun 16;48(12):3980-90.

PMID:
15943472

Supplemental Content

Loading ...
Support Center